FUSION PROTEIN COMPRISING IL-2 PROTEIN AND CD80 PROTEIN, AND USE THEREOF

The present invention provides a fusion protein comprising an IL-2 protein and a CD80 protein. A fusion protein comprising a CD80 fragment, an immunoglobulin Fc, and an IL-2 variant, in one embodiment, can activate immune cells, such as natural killer cells, and, at the same time, can control the im...

Full description

Saved in:
Bibliographic Details
Main Author JANG, Myung Ho
Format Patent
LanguageEnglish
French
Korean
Published 26.03.2020
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention provides a fusion protein comprising an IL-2 protein and a CD80 protein. A fusion protein comprising a CD80 fragment, an immunoglobulin Fc, and an IL-2 variant, in one embodiment, can activate immune cells, such as natural killer cells, and, at the same time, can control the immune cell regulatory activity of regulatory T cells. Therefore, a pharmaceutical composition comprising the fusion protein as an active ingredient can increase the immune activity in vivo and can be effectively used for not only cancer but also infectious diseases, and thus is highly industrially applicable. La présente invention concerne une protéine de fusion comprenant une protéine IL-2 et une protéine CD80. Selon un mode de réalisation de la présente invention, une protéine de fusion comprenant un fragment de CD80, une immunoglobuline Fc et un variant d'IL-2, peut activer des cellules immunitaires, telles que des cellules tueuses naturelles, et, en même temps, peut contrôler l'activité régulatrice des cellules immunitaires de lymphocytes T régulateurs. Par conséquent, une composition pharmaceutique comprenant la protéine de fusion en tant que principe actif peut augmenter l'activité immunitaire in vivo et peut être utilisée de manière efficace pour non seulement le cancer mais également des maladies infectieuses, et peut donc avoir des utilisations industrielles. IL-2 단백질 및 CD80 단백질을 포함하는 융합단백질을 제공한다. 일 구체예인 CD80 단편, 면역글로불린 Fc 및 IL-2 변이체를 포함하는 융합단백질은 자연살해세포와 같은 면역세포를 활성화시킬 수 있으며, 동시에 조절 T 세포의 면역세포 조절 활성을 제어할 수 있다. 따라서, 상기 융합단백질을 유효 성분으로 포함하는 약학 조성물은 체내의 면역활성을 증가시켜 암뿐만 아니라 감염성 질환에도 효과적으로 활용할 수 있어 산업적 활용 가능성이 높다.
Bibliography:Application Number: WO2019KR11928